Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

RAD Presentation March 2026

Tuesday, March 10, 2026 1 min read
Key Takeaway: Radiopharm Theranostics has made significant progress with its BetaBart (RV-01) program, having dosed the first patient in a Phase 1/2a clinical study. The company also received IND approval from the US FDA to initiate this therapeutic study targeting B7H3. Additionally, positive updates were shared across four of their clinical programs, indicating a strong outlook for the company.
Price reaction · baseline $4.99 (2026-03-10T17:29:00.000Z) · hit during market hours · clean, no other RADX news in the window
day 0 close · peak
-0.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Radiopharm Theranostics has initiated a Phase 1/2a clinical study.
  • The company received IND approval from the US FDA.
  • Positive clinical updates were provided across four programs.

Full Press Release Details

• Investor Presentations
• March 10, 2026
Loading Viewer…

More Announcements & Updates

• Announcements
• February 10, 2025
• Announcements
• October 25, 2022
• Announcements
• March 7, 2025
• Announcements
• August 21, 2024

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is the BetaBart (RV-01) study?

The BetaBart (RV-01) study is a Phase 1/2a clinical trial initiated by Radiopharm Theranostics.

What recent approval did Radiopharm receive?

Radiopharm Theranostics received IND approval from the US FDA for the BetaBart study.

When was the first patient dosed in the study?

The first patient in the BetaBart study was dosed in October 2025.

What updates were provided by Radiopharm?

Radiopharm shared positive clinical updates across four of its programs.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics BetaBart Phase 1/2a FDA IND approval B7H3
Last updated: Mar 10, 2026